Acasti announces appointment of new scientific advisory board members

Laval, qc , june 22, 2023 /prnewswire/ -- acasti pharma inc. ("acasti" or the "company") (nasdaq: acst), a late-stage, biopharma company advancing gtx-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced the appointment of w. taylor kimberly, md, phd, alejandro a.
ACST Ratings Summary
ACST Quant Ranking